MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/β-catenin pathway by targeting phospholipase D1

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: A Cancer J Clinic. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8:11884–11894.
   PubMed Web of Science ®Google Scholar
• Kumar M, Nanavati R, Modi TG, et al. Oral cancer: etiology and risk factors: a review. J Cancer Res Ther. 2016;12:458–463.
   PubMed Web of Science ®Google Scholar
• Ettinger KS, Ganry L, Fernandes RP. Oral cavity cancer. Oral and Maxillofacial Surg Clin N Am. 2019;31:13–29.
   PubMed Web of Science ®Google Scholar
• Huang SH, O'Sullivan B. Oral cancer: current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013;18:e233–40.
   PubMed Web of Science ®Google Scholar
• Speight PM, Farthing PM. The pathology of oral cancer. Br Dent J. 2018;225:841–847.
   PubMed Web of Science ®Google Scholar
• Huber MA, Tantiwongkosi B. Oral and oropharyngeal cancer. Med Clin North Am. 2014;98:1299–1321.
   PubMed Web of Science ®Google Scholar
• Irimie AI, Ciocan C, Gulei D, et al. Current insights into oral cancer epigenetics. IJMS. 2018;19:670.
   Web of Science ®Google Scholar
• Li Z, Xu R, Li N. MicroRNAs from plants to animals, do they define a new messenger for communication? Nutr Metab (Lond). 2018;15:68.
   PubMed Web of Science ®Google Scholar
• Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14.
   PubMed Web of Science ®Google Scholar
• Acunzo M, Croce CM. MicroRNA in cancer and cachexia–a mini-review. J Infect Dis. 2015;212:S74–S77.
   PubMed Web of Science ®Google Scholar
• Han YN, Xia SQ, Zhang YY, et al. Circular RNAs: a novel type of biomarker and genetic tools in cancer. Oncotarget 2017;8:64551–64563.
   PubMedGoogle Scholar
• Thyagarajan A, Shaban A, Sahu RP. MicroRNA-directed cancer therapies: implications in melanoma intervention. J Pharmacol Exp Ther. 2018;364:1–12.
   PubMed Web of Science ®Google Scholar
• Cheng J, Chen Y, Zhao P, et al. Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance. Oncol Lett. 2017;13:3859–3865.
   PubMed Web of Science ®Google Scholar
• Wang XX, Liu J, Tang YM, et al. MicroRNA-638 inhibits cell proliferation by targeting suppress PIM1 expression in human osteosarcoma. Tumour Biol: J Int Soc Oncodev Biol Med. 2016;37:16367–16375.
   Google Scholar
• Zhang J, Bian Z, Zhou J, et al. MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma. Protein Cell. 2015;6:680–688.
   PubMed Web of Science ®Google Scholar
• Li M, Wang J, Liu H. Downregulation of miR-638 promotes progression of breast cancer and is associated with prognosis of breast cancer patients. Ott. 2018;11:6871–6877.
   Web of Science ®Google Scholar
• Wei H, Zhang JJ, Tang QL. MiR-638 inhibits cervical cancer metastasis through Wnt/beta-catenin signalling pathway and correlates with prognosis of cervical cancer patients. Euro Rev Med Pharmacol Sci. 2017;21:5587–5593.
   PubMed Web of Science ®Google Scholar
• Sciubba JJ, Larian B. Oral squamous cell carcinoma: early detection and improved 5-year survival in 102 patients. General Dentistry 2018;66:e11–e16.
   PubMedGoogle Scholar
• Prasad G, Seers C, Reynolds E, et al. A panel of microRNAs can be used to determine oral squamous cell carcinoma. J Oral Pathol Med: Off Public Int Assoc Oral Pathol Am Acad Oral Pathol. 2017;46:940–948.
   Google Scholar
• Shen Y, Chen H, Gao L, et al. MiR-638 acts as a tumour suppressor gene in gastric cancer. Oncotarget 2017;8:108170–108180.
   PubMedGoogle Scholar
• Shi M, Jiang Y, Yang L, et al. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. J Cell Biochem. 2018;119:47116.
   Web of Science ®Google Scholar
• Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol. 2017;1509:1–10.
   PubMedGoogle Scholar
• Brown HA, Thomas PG, Lindsley CW. Targeting phospholipase D in cancer, infection and neurodegenerative disorders. Nat Rev Drug Disc. 2017;16:351–367.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Frohman MA. Cellular and physiological roles for phospholipase D1 in cancer. J Biol Chem. 2014;289:22567–22574.
   PubMed Web of Science ®Google Scholar
• Tang W, Liang R, Duan Y, et al. PLD1 overexpression promotes invasion and migration and function as a risk factor for Chinese glioma patients. Oncotarget 2017;8:57039–57046.
   PubMedGoogle Scholar
• Xiao J, Sun Q, Bei Y, et al. Therapeutic inhibition of phospholipase D1 suppresses hepatocellular carcinoma. Clin Sci (Lond). 2016;130:1125–1136.
   PubMed Web of Science ®Google Scholar
• Gadiya M, Mori N, Cao MD, et al. Phospholipase D1 and choline kinase-alpha are interactive targets in breast cancer. Cancer Biol Ther. 2014;15:593–601.
   PubMed Web of Science ®Google Scholar
• Kang DW, Lee SH, Yoon JW, et al. Phospholipase D1 drives a positive feedback loop to reinforce the Wnt/beta-catenin/TCF signalling axis. Cancer Res. 2010;70:4233–4242.
   PubMed Web of Science ®Google Scholar
• Kang DW, Lee BH, Suh YA, et al. Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by wnt/beta-catenin and PI3K/Akt signalling. Clin Cancer Res. 2017;23:7340–7350.
   PubMed Web of Science ®Google Scholar
• Kang DW, Min do S. Positive feedback regulation between phospholipase D and Wnt signalling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells. PloS One. 2010;5:e12109.
   PubMed Web of Science ®Google Scholar
• Rheinwald JG, Beckett MA. Tumourigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res. 1981;41:1657–1663.
   PubMed Web of Science ®Google Scholar